TG Therapeutics Prelim. Q4 BRIUMVI Rev $103.6M; FY2025 US Revenue Target $525M

TG THERAPEUTICS, INC.

Preliminary Q4 2024 BRIUMVI U.S. net product revenue $103.6M; full year 2024 $310M.
FY2025 target total global revenue ~$540M, including BRIUMVI U.S. net product revenue ~$525M; target opex ~$300M.
2025 milestones: commence pivotal program for subcutaneous BRIUMVI; evaluate 30-min infusion; enroll in autoimmune trials.
Year-end 2024 cash position approx. $310M.
CEO states 2024 revenue far exceeded initial expectations; BRIUMVI well positioned for continued growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.